Mapati

Pourouma cecropiifolia fruit contains phenolic bioactives—principally epicatechin, caffeic acid, chlorogenic acid isomers, procyanidin B2, nortracheloside, and trans-resveratrol—that exert antioxidant activity via ROS scavenging and inhibit cancer-associated cytochrome P450 enzymes CYP1A1 and CYP1B1 through direct molecular docking interactions. Seed hydroethanolic extracts demonstrate the most potent bioactivity, showing cytotoxicity against MCF-7 breast cancer cells at 50.6 μg GAE/mL in vitro and reducing artesunate IC₅₀ against Plasmodium falciparum by 85% at 10 μg GAE/mL, though no human clinical trials have yet been conducted.

Origin & History

Pourouma cecropiifolia is a dioecious tree native to the western Amazon basin, distributed across Peru, Colombia, Ecuador, and Brazil, where it thrives in humid tropical lowland forests at elevations below 1,000 meters. The species belongs to the family Urticaceae and produces grape-like clusters of dark-purple fruit colloquially called 'uva caimarona' or mapati, harvested from semi-domesticated trees maintained by indigenous communities. It grows in rich alluvial soils along riverbanks and forest edges, and is occasionally cultivated in home gardens and agroforestry systems throughout Amazonia.

Historical & Cultural Context

Pourouma cecropiifolia has been cultivated and harvested by indigenous Amazonian communities—including groups in the Peruvian and Colombian Amazon—primarily as a food crop, with the sweet, grape-flavored fruit consumed fresh or fermented into traditional beverages during seasonal harvests. The tree holds cultural significance as a managed species in Amazonian agroforestry systems, where it is propagated from seed or cuttings and integrated into multi-strata home gardens ('chacras') alongside other native fruit trees. Detailed ethnopharmacological records specifically documenting its use as a medicinal plant are sparse in the peer-reviewed literature, though related Pourouma and Cecropia species within Urticaceae have documented traditional uses for anti-inflammatory and antimalarial preparations across the Amazon basin. Modern scientific interest has shifted focus toward systematic bioprospecting of the fruit fractions using advanced analytical platforms (UPLC-QTOF-MS, HPLC-DAD), moving beyond traditional food use to explore pharmaceutical and nutraceutical potential.

Health Benefits

- **Antioxidant Protection**: Seed extracts exhibit the strongest free-radical scavenging capacity as measured by DPPH, FRAP, and HRSA assays, with seed tissue containing 23.18 ± 0.04 mg GAE g⁻¹ total phenolics (dry weight), driven by high concentrations of procyanidin B2, caffeic acid, and chlorogenic acid isomers.
- **Anticancer Potential**: In vitro antiproliferative activity has been recorded against MCF-7 breast cancer cells, HeLa cervical cancer cells, RKO colorectal cells, and T47D breast cancer cells; seed and peel extracts show cytotoxic thresholds of 50.6 and 104 μg GAE/mL, respectively, attributed to CYP1A1/CYP1B1 enzyme inhibition by epicatechin, caffeic acid, and nortracheloside.
- **Genoprotective Activity**: At concentrations of 12.5–20 μg GAE/mL, hydroethanolic extracts significantly reduced DNA strand fragmentation and chromosomal aberrations in cell-based genotoxicity assays, suggesting antimutagenic capacity linked to phenolic antioxidant content.
- **Antimalarial Activity**: Peel and seed extracts display activity against both chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strains of Plasmodium falciparum in vitro, with seed extract potentiating artesunate efficacy by reducing its IC₅₀ by 85% at 10 μg GAE/mL, indicative of synergistic antimalarial properties.
- **Anti-inflammatory Potential**: Quercetin glycosides and caffeic acid present in peel and seed fractions are structurally associated with NF-κB pathway modulation and cyclooxygenase inhibition in related species, though direct anti-inflammatory assays in Pourouma cecropiifolia remain to be published.
- **Cardiovascular Bioactive Profile**: The peel contains 21.00 ± 0.30 µg g⁻¹ trans-resveratrol and 8.43 ± 0.04 mg g⁻¹ anthocyanins, compounds widely associated with endothelial protection and platelet aggregation inhibition in the broader phytochemical literature, though species-specific cardiovascular data are not yet available.
- **Vitamin C and Micronutrient Contribution**: Peel tissue provides 4.67 ± 0.28 mg ascorbic acid per 100 g (dry weight), contributing to dietary antioxidant intake, while the seed fraction's dense polyphenol matrix may enhance iron absorption and modulate oxidative stress in erythrocytes, as suggested by hemolysis-protective data from HRSA assays.

How It Works

The dominant mechanistic pathway identified involves direct inhibition of aryl hydrocarbon receptor-regulated cytochrome P450 enzymes implicated in carcinogen bioactivation: in silico molecular docking studies reveal caffeic acid binds CYP1A1 with a binding energy of -10.7 kcal mol⁻¹, epicatechin binds CYP1B1 at -10.3 kcal mol⁻¹, and nortracheloside binds CYP1A1 at -9.2 kcal mol⁻¹, suggesting competitive inhibition that may reduce metabolic activation of procarcinogens. Antioxidant mechanisms operate through direct hydrogen atom transfer and electron donation by polyphenols—particularly procyanidin B2 and chlorogenic acid—to neutralize reactive oxygen species (ROS), as validated by significant reductions in intracellular ROS in A549 lung cancer cells and protective effects on human erythrocyte membrane integrity in HRSA assays. Antimalarial activity appears to operate via a synergistic mechanism with artesunate, where seed phenolics may interfere with heme detoxification pathways in Plasmodium falciparum or inhibit parasite-specific efflux pumps, effectively re-sensitizing resistant W2 strains; the 85% reduction in artesunate IC₅₀ at 10 μg GAE/mL supports a pharmacodynamic potentiation model. Genoprotective effects are attributed to the combined antioxidant suppression of oxidative DNA damage and potential modulation of phase II detoxification enzymes, reducing chromosomal aberration rates and DNA fragmentation at sub-cytotoxic concentrations (12.5–20 μg GAE/mL).

Scientific Research

The current evidence base for Pourouma cecropiifolia is limited exclusively to in vitro cell-based studies and in silico computational modeling, with no published human clinical trials, animal intervention studies, or pharmacokinetic data identified as of the most recent literature review. Key published work includes UPLC-QTOF-MS phytochemical profiling of hydroethanolic peel, pulp, and seed extracts; DPPH/FRAP/HRSA antioxidant assays; antiproliferative MTT assays against five cancer cell lines (A549, MCF-7, HeLa, RKO, T47D); Plasmodium falciparum 3D7/W2 in vitro antimalarial screens; and Ames-type genotoxicity/antigenotoxicity assays. Molecular docking computations provide mechanistic hypotheses for CYP1A1/CYP1B1 inhibition but have not been validated by biochemical enzyme assays or cell-based CYP reporter systems. The overall evidence quality is preliminary: findings are hypothesis-generating rather than confirmatory, effect magnitudes are reported only at fixed extract concentrations without dose-response modeling, and the absence of bioavailability data makes translation to physiological relevance highly uncertain.

Clinical Summary

No human clinical trials investigating Pourouma cecropiifolia have been identified in any published literature or registered clinical trial databases. All efficacy data derive from cell culture experiments using defined cancer cell lines and Plasmodium falciparum cultures, supplemented by computational docking studies; these experimental models provide mechanistic plausibility but cannot establish clinical efficacy, optimal dosing, or human safety. Effect sizes such as the 85% reduction in artesunate IC₅₀ and cytotoxic activity at 50.6 μg GAE/mL are meaningful in vitro benchmarks but lack corresponding pharmacokinetic context to determine whether similar concentrations are achievable in human plasma or target tissues. Confidence in any therapeutic claim must therefore remain very low pending at minimum in vivo animal studies, bioavailability characterization, and ultimately randomized controlled trials in human populations.

Nutritional Profile

The pulp of Pourouma cecropiifolia contains modest total phenolics (0.30 ± 0.01 mg GAE g⁻¹ d.w.) and low flavonoids (0.03 ± 0.00 mg QE g⁻¹), with a small anthocyanin fraction (0.16 mg g⁻¹) and 2.60 µg g⁻¹ trans-resveratrol; ascorbic acid is absent in the pulp but present in the peel (4.67 ± 0.28 mg 100 g⁻¹ d.w.). The peel is nutritionally distinguished by high anthocyanin content (8.43 ± 0.04 mg g⁻¹), the highest trans-resveratrol concentration across all fruit parts (21.00 ± 0.30 µg g⁻¹), and measurable flavonoids (0.13 ± 0.00 mg QE g⁻¹). The seed fraction is phytochemically richest, with 23.18 ± 0.04 mg GAE g⁻¹ total phenolics, 0.31 ± 0.00 mg QE g⁻¹ flavonoids, and 1.80 mg g⁻¹ anthocyanins; however, seeds are not a typical dietary component. Identified phytochemicals include epicatechin, quercetin glycosides, caffeic acid, chlorogenic acid isomers, neoolivil (a lignan), procyanidin B2, nortracheloside (an iridoid glycoside), terpene derivatives, curcuminoids, and naphthodianthrone; standard macronutrient composition (carbohydrates, protein, fat, fiber) has not been formally published, and bioavailability data for any constituent are absent.

Preparation & Dosage

- **Hydroethanolic Extract (Research Grade)**: Concentrations of 12.5–104 μg GAE/mL have been used in cell-based studies; no equivalent human oral dose has been established, and these figures reflect in vitro test concentrations only.
- **Fresh Fruit (Traditional Consumption)**: The ripe fruit is consumed fresh in Amazonian communities, typically eating the pulp directly or preparing fermented beverages; no standardized intake quantity has been documented in ethnobotanical literature.
- **Seed Fraction**: Seeds contain the highest phenolic density (23.18 mg GAE g⁻¹ d.w.) and strongest bioactivity in vitro; however, seeds are not consumed as food in traditional practice and no safe oral preparation method has been validated.
- **Peel Extract**: Peel provides peak trans-resveratrol (21.00 µg g⁻¹) and anthocyanin (8.43 mg g⁻¹) concentrations; again, no oral supplement form or standardized extract is commercially available.
- **No Commercial Supplement Form Exists**: As of current literature, Pourouma cecropiifolia is not available as a standardized commercial dietary supplement (capsule, powder, tincture, or standardized extract), and no evidence-based dosing guideline can be provided.

Synergy & Pairings

In vitro data demonstrate that seed extract of Pourouma cecropiifolia acts synergistically with artesunate against Plasmodium falciparum, reducing artesunate's IC₅₀ by 85% at 10 μg GAE/mL, suggesting that its phenolic constituents (potentially procyanidin B2 or chlorogenic acid) may inhibit parasite drug efflux or enhance oxidative parasite damage alongside the artemisinin mechanism. The co-occurrence of trans-resveratrol, epicatechin, and anthocyanins in the peel fraction mirrors the polyphenol synergy described in red grape skin extracts, where these compounds collectively enhance endothelial nitric oxide bioavailability and antioxidant network recycling—though this synergy has not been directly tested in Pourouma cecropiifolia. Combining phenolic-rich seed or peel extracts with vitamin C (present in the peel itself) may theoretically support anthocyanin stability and extend the half-life of catechin radical species, a mechanism documented for polyphenol-ascorbate co-administration in related berry species.

Safety & Interactions

No human safety data, adverse event reports, maximum tolerated doses, or formal toxicological studies have been published for Pourouma cecropiifolia extracts or fruit fractions; the complete absence of in vivo and clinical safety evaluation means that the risk profile in humans is entirely unknown. In vitro antigenotoxic and antimutagenic activity at 12.5–20 μg GAE/mL suggests the extract does not appear mutagenic at these concentrations in cell-based assays, but this does not constitute evidence of systemic safety in humans. No documented drug interactions exist, though the presence of caffeic acid and quercetin glycosides raises theoretical concerns regarding interactions with cytochrome P450-metabolized drugs (particularly CYP1A2 substrates such as theophylline and certain chemotherapeutics) given the demonstrated in silico CYP1A1 inhibitory activity. Guidance for use during pregnancy, lactation, or in pediatric populations cannot be provided given the complete absence of relevant data, and consumption beyond traditional food use of the fresh fruit is not advisable without further safety characterization.